Result card

  • EFF2a: Are IVIG effective in improving neuropsychiatric symptoms in patients Mild Cognitive Impairment when compared to placebo?
  • EFF2b: Are IVIG effective in improving behavioural symptoms in patients with mild-to-moderate Alzheimer’s disease when compared to placebo or acetyl cholinesterase inhibitors? Jump to
  • EFF2c: Are IVIG effective in improving behavioural symptoms in patients with moderate-to-severe Alzheimer’s disease when compared to placebo or memantine? Jump to
English

Are IVIG effective in improving neuropsychiatric symptoms in patients Mild Cognitive Impairment when compared to placebo?

Authors: Luca Vignatelli, Luciana Ballini, Susanna Maltoni, Jelena Barbaric, Mirjana Huic, Pernilla Östlund.

Internal reviewers: Gerardo Atienza, Agnes Mannik

The same methodology was used as described in section for the whole domain.

No evidence is available on effectiveness of IVIG for patients with MCI.

Important
Completely
Vignatelli L et al. Result Card EFF2a In: Vignatelli L et al. Clinical Effectiveness In: Jefferson T, Cerbo M, Vicari N [eds.]. Use of Intravenous immunoglobulins for Alzeheimer’s disease including Mild Cognitive Impairment [Core HTA], Agenas - Agenzia nazionale per i servizi sanitari regionali ; 2015. [cited 30 October 2020]. Available from: http://corehta.info/ViewCover.aspx?id=267

Are IVIG effective in improving behavioural symptoms in patients with mild-to-moderate Alzheimer’s disease when compared to placebo or acetyl cholinesterase inhibitors?

Authors: Luca Vignatelli, Luciana Ballini, Susanna Maltoni, Jelena Barbaric, Mirjana Huic, Pernilla Östlund.

Internal reviewers: Gerardo Atienza, Agnes Mannik

The same methodology was used as described in section for the whole domain.

Data on behavioural changes, measured by NPI, were available from 300 patients (out of 383) of one RCT {NCT00818662}.

Mean score change from baseline at 18 months in NPI assessment did not differ between IVIG 400 mg/kg group (104 patients) and placebo group (94 patients) (0.7 point score of difference, 95%CI -2.1 to 3.4, P = 0.640) and between IVIG 200 mg/kg group (102 patients) and placebo group (94 patients) (2.5 point score of difference, 95CI -0.3 to 5.3, P = 0.075). See Appendix 2 for details.

Table 2. Summary of findings: behavioural changes in patients with mild-to-moderate AD treated with IVIG

OutcomeMean difference between IVIG 400mg/kg and PlaceboMean difference between IVIG 200mg/kg and PlaceboConfidence in effect estimate
Behaviour: NPI mean score change from baseline to 18 months0.7 (95% CI  -2.1 to 3.4); P = 0.6402.5 (95% CI -0.3 to 5.3); P = 0.075Very low

 

Critical
Completely
Vignatelli L et al. Result Card EFF2b In: Vignatelli L et al. Clinical Effectiveness In: Jefferson T, Cerbo M, Vicari N [eds.]. Use of Intravenous immunoglobulins for Alzeheimer’s disease including Mild Cognitive Impairment [Core HTA], Agenas - Agenzia nazionale per i servizi sanitari regionali ; 2015. [cited 30 October 2020]. Available from: http://corehta.info/ViewCover.aspx?id=267

Are IVIG effective in improving behavioural symptoms in patients with moderate-to-severe Alzheimer’s disease when compared to placebo or memantine?

Authors: Luca Vignatelli, Luciana Ballini, Susanna Maltoni, Jelena Barbaric, Mirjana Huic, Pernilla Östlund.

Internal reviewers: Gerardo Atienza, Agnes Mannik

The same methodology was used as described in section for the whole domain.

No evidence is available on effectiveness of IVIG for patients with moderate-to-severe AD.

Critical
Completely
Vignatelli L et al. Result Card EFF2c In: Vignatelli L et al. Clinical Effectiveness In: Jefferson T, Cerbo M, Vicari N [eds.]. Use of Intravenous immunoglobulins for Alzeheimer’s disease including Mild Cognitive Impairment [Core HTA], Agenas - Agenzia nazionale per i servizi sanitari regionali ; 2015. [cited 30 October 2020]. Available from: http://corehta.info/ViewCover.aspx?id=267

References